This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baudin, E. Articles by Schlumberger, M. Search for Related Content PubMed PubMed Citation Articles by Baudin, E. Articles by Schlumberger, M.

Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors¹

Nuclear Medicine (E.B., M.S.), Clinical Biology (J.M.B., V.L., F.T., E.C.), Medicine (Ph.R., P.R., M.D.), Biostatistics and Epidemiology (J.R.), Pathology (J.-C.S.), Surgery (P.L.), and Interventional Radiology (T.D.), Institut Gustave-Roussy, 94805 Villejuif Cedex, France

Address all correspondence and requests for reprints to: Dr. Eric Baudin, Service de Médecine Nucléaire, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail: baudin{at}igr.fr

Screening was performed in 130 consecutive patients with apparently sporadic neuroendocrine tumors (NET) to assess the prevalence of multiple endocrine neoplasia type 1 (MEN1) and hormonal production. Screening for MEN1 included measurement of serum calcium and PTH [PTH-(1–84)], gastrin, PRL, and insulin-like growth factor type I (IGF-I) levels. MEN1 genetic testing was performed in patients with two components of the MEN1 syndrome. Screening for hormonal production included measurement of serum neuron-specific enolase (NSE), calcitonin (CT), glycoprotein -subunit (GP), hCG ß-subunit (free hCGß), and somatostatin levels. Twenty-four-hour urinary free cortisol (UFC) and 5-hydroxyindolacetic acid (5-HIAA) determinations were also performed. Four patients had hyperparathyroidism, none of whom had pituitary or familial disease. Hyperprolactinemia was compatible with a pituitary disease in one patient. No acromegalic feature or any increase in IGF-I was found. Hypergastrinemia, compatible with an associated pancreatic NET, was found in one patient. Genetic screening of the MEN1 gene was performed in five of the six patients with two components of the MEN1 syndrome. A nonsense mutation (Arg¹⁰⁸stop) was identified in the tumor of one patient. Elevated NSE, 5-HIAA, CT, GP, free hCGß, SMS, and nonsuppressible UFC were found in 47%, 46%, 14%, 19%, 12%, 3%, and 6% of NET patients, respectively. Production of CT, GP, and free hCGß was highly related to the primary site: all but two of these secretions originated in foregut NET. 5-HIAA secretion was found in 27% of foregut-derived and 85% of midgut-derived NET.

In conclusion, MEN1 is a rare event in patients presenting with apparently sporadic NET. It occurred mainly in foregut NET and should be screened for by serum calcium and PTH-(1–84) measurements. Routine hormonal measurements should depend on the primary site. NSE, 5-HIAA, CT, and GP should be routinely measured in foregut-derived NET; only serum NSE and 5-HIAA measurements are recommended in midgut-derived NET.

This article has been cited by other articles:

				C. Durante, H. Boukheris, C. Dromain, P. Duvillard, S. Leboulleux, D. Elias, T. de Baere, D. Malka, J. Lumbroso, J. Guigay, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma Endocr. Relat. Cancer, June 1, 2009; 16(2): 585 - 597. [Abstract] [Full Text] [PDF]

				G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]

				E. Bajetta, L. Ferrari, G. Procopio, L. Catena, E. Ferrario, A. Martinetti, M. Di Bartolomeo, R. Buzzoni, L. Celio, M. Vitali, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours Ann. Onc., April 1, 2002; 13(4): 614 - 621. [Abstract] [Full Text] [PDF]